Back to search
Gastro Esophageal Reflux Disease PPI Non-Responders
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Gastro Esophageal Reflux Disease PPI Non-Responders trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Gastro Esophageal Reflux Disease PPI Non-Responders trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The prevalence of GERD is estimated to be as high as 20% in the US, and up to 50% remain symptomatic on proton pump inhibitor (PPI) therapy. The clinical approa…
Gastroesophageal reflux disease (GERD) is a common chronic condition, affecting approximately 20% of the American adult population. Proton pump inhibitors (PPIs…
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (s…